Description

This session will provide insights on moving from the traditional regulatory strategies for mature technologies to the new regulatory strategies for novel uses of AI and ML while engaging FDA and/or Notified Bodies in the effort.

The IMDRF, US, and EU perspectives on what's next for AI and ML as SaMD will be explored.

Areas Covered:-

• Describe actual and future AI applications that are changing patient treatment and healthcare delivery through the exploration of real-world examples (across different diagnostic/therapeutic and technology areas)
• Demonstrate knowledge of US and EU perspectives on current developments and challenges stemming from the development and implementation of AI/ML in the development of regulatory strategies
• Develop and execute regulatory strategies that meet real-world needs posed by AI and ML

Why should you Attend:-

This session will engage professionals looking to understand the regulatory challenges of software as a medical device (SaMD) with a special focus on AI/Machine Learning (ML).

Who Should Attend:-

• VP of IT
• Director of IT
• Quality Managers
• Project Managers (for CSV / IT)
• Validation Specialists
• Database Administrators
• System Administrators
• Directors / Senior Directors of Discovery
• Directors / Senior Directors of Development
• Directors / Senior Directors of Commercialization
• Document Managers
• Training Managers
• Regulators